LENZ Therapeutics, Inc. (LENZ)
$3.61-1.10%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $113M
- Beta
- 1.63
- P/E (TTM)
- -0.93
- Short % float
- 38.60%
- Days to cover
- 13.8
- SI change
- -0.7%
- 1W
- +0.56%
- 1M
- -20.13%
- vs SPY 1W
- +0.14%
- vs SPY 1M
- -22.19%
Industry peers
FMP comparable companies · ranked by market cap
- MRVIBUYMaravai LifeSciences Holdings, Inc.$2.1BCRISISQ -2$7.44-5.11%
- GHRSSELLGH Research PLC$1.4BCRISISQ 15$21.11-5.16%
- NBTXSELLNanobiotix S.A.$1.2BCRISISQ 17$23.68-1.18%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$19.94-1.71%
- SVRASELLSavara Inc.$1.0BRECOVERYQ 11$4.92-1.63%
- ABUSSELLArbutus Biopharma Corp$834MCRISISQ 13$4.22-1.66%
- GERNSELLGeron Corporation$786MRECOVERYQ 11$1.23-0.81%
- PRMEBUYPrime Medicine, Inc.$721MRECOVERYQ -7$3.99-9.52%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on LENZ?
- LOPJLB’s latest quantitative signal on LENZ Therapeutics, Inc. (LENZ) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LENZ in?
- LENZ Therapeutics, Inc. (LENZ) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does LENZ Therapeutics, Inc. (LENZ) do?
- LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyop…